Patent application number | Description | Published |
20100093724 | Azaindazole Compounds As CCR1 Receptor Antagonists - Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. | 04-15-2010 |
20110034512 | Indazole Compounds As CCR1 Receptor Antagonists - Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 02-10-2011 |
20110086846 | Azaindazole Compounds As CCR1 Receptor Antagonists - Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. | 04-14-2011 |
20110230521 | Pyrazole Compounds As CCR1 Antagonists - Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 09-22-2011 |
20110294808 | Indazole Compounds As CCR1 Receptor Antagonists - Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 12-01-2011 |
20120035370 | Azaindazole Compounds As CCR1 Receptor Antagonists - Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. | 02-09-2012 |
20120136158 | Pyridinyl Compounds Useful As Intermediates - Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. | 05-31-2012 |
20120270870 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists - Diclosed are CCR1 receptor antagonists of the formula (I) | 10-25-2012 |
20120322790 | Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists - Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. | 12-20-2012 |
Patent application number | Description | Published |
20080199418 | Polysiloxane block copolymers - This invention encompasses novel amphiphilic block copolymers comprising polysiloxane blocks and polycationic blocks. The polycationic blocks are formed from diallyldialkylammonium derivatives. The formed block copolymers are particularly useful for treating or conditioning keratinous substances such as hair or skin. | 08-21-2008 |
20090214447 | Preparation of cationic nanoparticles and personal care compositions comprising said nanoparticles - The present invention is directed to cationic nanoparticles, methods to make them, and the use of compositions containing said nanoparticles in personal care compositions or formulations. The nanoparticles are useful in personal care applications and impart antimicrobial properties to home and personal care products containing them. These cationic nanoparticles also contribute useful conditioning properties to hair-care and skin-care products. | 08-27-2009 |
20100108955 | Polyelectrolyte complexes as thickeners for high ionic strength salt solutions - A polyelectrolyte complex composition capable of viscosifying or thickening an aqueous high salt-containing system comprises a mixture of at least one anionic polymer and at least one cationic polymer in an inorganic salt-containing aqueous medium. The anionic polymer and cationic polymer can each be linear and water-soluble, crosslinked and water-soluble, or crosslinked and water-insoluble or swellable. | 05-06-2010 |
20100303750 | POLYSILOXANE BLOCK COPOLYMERS - This invention encompasses novel amphiphilic block copolymers comprising polysiloxane blocks and polycationic blocks. The polycationic blocks are formed from diallyldialkylammonium derivatives. The formed block copolymers are particularly useful for treating or conditioning keratinous substances such as hair or skin. | 12-02-2010 |
Patent application number | Description | Published |
20100041645 | RHO KINASE INHIBITORS - Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma. | 02-18-2010 |
20100210627 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION - The invention provides compounds according to formula (I) | 08-19-2010 |
20110230521 | Pyrazole Compounds As CCR1 Antagonists - Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 09-22-2011 |
20110275612 | ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM - Disclosed is a compound of formula (I). Wherein R | 11-10-2011 |
20140045813 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS - The present invention encompasses compounds of the formula (I) | 02-13-2014 |
20140275012 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS - The present invention encompasses compounds of the formula (I) | 09-18-2014 |